Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement...

Related Keywords

New Jersey ,United States ,Switzerland ,Swiss ,American ,Karenm King ,Pramod Theetha Kariyann ,Alysiak Kemp ,Chris Lewis ,Apoorva Jayarangaiah ,Joerge Allgaeuer ,National Center ,American Cancer Society ,Osteoporosis Foundation ,Us Federal District Court ,Amgen ,Drug Administration ,Swiss Exchange Listing ,Health Statistics ,Bone Health ,National Institute Of Arthritis ,Amgen Inc ,Exchange Listing ,District Court ,Biologics Price Competition ,Innovation Act ,Active Ingredient ,Following Treatment Discontinuation ,Giant Cell Tumor ,Growing Skeletons ,Vertebral Fractures ,Fetal Toxicity ,Solid Tumors ,Cell Tumor ,Low Bone Mass ,Older Adults ,Osteoporosis Fast ,Media Release ,Calcium Sandoz ,Media Relations ,Release Deno Agreement ,Markets ,